Hepalink Pharmaceutical details share structure, governance in new document

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has issued its Articles of Association, detailing its corporate structure and share capital. The company, established in December 2007, currently has 1,467,296,204 shares in issue, comprising 1,247,201,704 A shares (approximately 85% of total capital) and 220,094,500 H shares (approximately 15% of total capital). Its registered capital stands at 1,467,296,204 yuan.

The Articles also specify the company's business scope, which includes the development, production, and sale of heparin APIs, as well as import/export of goods and technologies. Governance is overseen by a seven-member board of directors, including three independent directors, with the chairman serving as the legal representative.

Key provisions address profit distribution, outlining a policy that prioritizes cash dividends and requires a minimum of 10% of distributable profits annually. Special resolutions are mandated for significant corporate actions like capital increases/reductions, mergers, and substantial asset transactions exceeding 30% of audited total assets.